Bristol Myers Squibb Receives European Commission Approval of Reblozyl (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission

Related Keywords

United Kingdom ,Norway ,Iceland ,United States ,Liechtenstein ,Canada ,Scotland ,Britain ,Dennis Riedl ,Origar Beta ,Noah Berkowitz ,Bristol Myers Squibb ,Instagram ,Linkedin ,Twitter ,Hematology Development ,Drug Administration ,European Commission ,Exchange Commission ,Youtube ,European Union ,Facebook ,Acceleron Pharma Inc ,Myers Squibb ,Marketing Authorization ,Bristol Myers ,Acceleron Pharma ,Centralized Marketing Authorization ,Great Britain ,Screening Period ,Double Blind Treatment Period ,Post Treatment Follow Up Period ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Accessed February ,Bristol ,Myers ,Squibb ,Eceives ,European ,Commission ,Approval ,Reblozyl ,Luspatercept ,Anemia ,Adult ,Patients ,Transfusion ,Idependent ,Meta ,Thalassemia ,